Franchimont相关文献与解析，生知库 | 链接生命科学的每一步

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo-Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines

利替菲利单抗在随机、安慰剂对照的 II 期研究中对狼疮的药效学作用：I 型干扰素相关基因表达和细胞因子的快速和持续降低

Furie, Richard; Werth, Victoria P; Milliman, Eric; Ferber, Kyle; Brown, Roland; Zoghbi, Jad; Franchimont, Nathalie; Lahoud, Youmna; Barbey, Catherine

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏

A transcriptomic score to classify the inflammation-dysplasia-cancer sequence lesions in inflammatory bowel disease

用于对炎症性肠病中的炎症-发育不良-癌变序列病变进行分类的转录组评分

期刊:Journal of Crohns & Colitis

影响因子:8.7

doi:10.1093/ecco-jcc/jjaf026

Cremer, Anneline; Rosewick, Nicolas; Kelsey, Maxfield; Trépo, Eric; Libert, Frédérick; De Vos, Martine; Baert, Filip; Moreels, Tom; Louis, Edouard; Rahier, Jean-François; Demetter, Pieter; Sedivy, John M; Vermeire, Séverine; Franchimont, Denis

Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST Study

炎症性肠病日常临床实践中的疾病监测及其对治疗决策的影响：来自炎症性肠病-PODCAST研究的真实世界证据

期刊:United European Gastroenterology Journal

影响因子:6.7

doi:10.1002/ueg2.70117

Dignass, Axel; Magro, Fernando; D'Amico, Ferdinando; Bamias, Giorgos; Caprioli, Flavio Andrea; Franchimont, Denis; Hart, Ailsa; Koch, Robert; Koutroubakis, Ioannis; Siffledeen, Jesse; Toruner, Murat; Leitner, Claudia; Heatta-Speicher, Tobias; Michelena, Naiara; Tornatore, Valentina; Gemignani, Lorenzo; Lapthorn, Jennifer; Kauffman, Laura; Gomollón, Fernando

The identification of blood-derived response eQTLs reveals complex effects of regulatory variants on inflammatory and infectious disease risk.

血液衍生反应 eQTL 的鉴定揭示了调控变异对炎症和传染病风险的复杂影响

期刊:PLoS Genetics

影响因子:3.7

doi:10.1371/journal.pgen.1011599

Liefferinckx Claire, Stern David, PerÃ©e HÃ©lÃ¨ne, Bottieau JÃ©rÃ©mie, Mayer Alice, Dubussy Christophe, Quertinmont Eric, Tafciu Vjola, Minsart Charlotte, Petrov Vyacheslav, Kvasz Alex, Coppieters Wouter, Karim Latifa, Rahmouni Souad, Georges Michel, Franchimont Denis

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary

利替利单抗治疗系统性红斑狼疮的LILAC研究A部分：简明语言摘要

期刊:Immunotherapy

影响因子:2.3

doi:10.1080/1750743X.2025.2459054

Furie, Richard A; van Vollenhoven, Ronald F; Kalunian, Kenneth; Navarra, Sandra; Romero-Diaz, Juanita; Werth, Victoria; Huang, Xiaobi; Carroll, Hua; Meyers, Adam; Musselli, Cristina; Franchimont, Nathalie; Barbey, Catherine

Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary

LILAC 研究 B 部分：利替利单抗治疗皮肤红斑狼疮的简明摘要

期刊:Immunotherapy

影响因子:2.3

doi:10.1080/1750743X.2025.2459053

Werth, Victoria P; Furie, Richard A; Romero-Diaz, Juanita; Navarra, Sandra; Kalunian, Kenneth; van Vollenhoven, Ronald F; Nyberg, Filippa; Kaffenberger, Benjamin H; Sheikh, Saira Z; Radunovic, Goran; Huang, Xiaobi; Carroll, Hua; Naik, Himanshu; Gaudreault, Francois; Meyers, Adam; Musselli, Cristina; Franchimont, Nathalie; Barbey, Catherine

Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial

Zasocitinib (TAK-279) 抑制酪氨酸激酶 2 治疗银屑病：一项随机临床试验

期刊:Jama Dermatology

影响因子:11

doi:10.1001/jamadermatol.2024.2701

Armstrong, April W; Gooderham, Melinda; Lynde, Charles; Maari, Catherine; Forman, Seth; Green, Lawrence; Laquer, Vivian; Zhang, Xinyan; Franchimont, Nathalie; Gangolli, Esha A; Blau, Jessamyn; Zhao, Yiwei; Zhang, Wenwen; Srivastava, Bhaskar; Heap, Graham; Papp, Kim

Editorial: Cutaneous lupus erythematosus landscape: pathophysiology, unmet needs, and related challenges in clinical practice. What is on the horizon?

社论：皮肤红斑狼疮的现状：病理生理学、未满足的需求以及临床实践中的相关挑战。未来发展趋势是什么？

期刊:Frontiers in Medicine

影响因子:3

doi:10.3389/fmed.2024.1373552

Merola, Joseph F; Nyberg, Filippa; Franchimont, Nathalie; Barbey, Catherine; Werth, Victoria P

Inhibition of RIPK1 kinase does not affect diabetes development: β-Cells survive RIPK1 activation

抑制RIPK1激酶并不影响糖尿病的发生发展：β细胞在RIPK1激活后仍能存活。

期刊:Molecular Metabolism

影响因子:6.6

doi:10.1016/j.molmet.2023.101681

Takiishi, Tatiana; Xiao, Peng; Franchimont, Marie; Gilglioni, Eduardo H; Arroba, Erick N; Gurzov, Esteban N; Bertrand, Mathieu Jm; Cardozo, Alessandra K

A machine learning framework reveals key drivers of cytokine responses in a healthy human cohort

机器学习框架揭示了健康人群中细胞因子反应的关键驱动因素

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo-Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines

利替菲利单抗在随机、安慰剂对照的 II 期研究中对狼疮的药效学作用：I 型干扰素相关基因表达和细胞因子的快速和持续降低

A transcriptomic score to classify the inflammation-dysplasia-cancer sequence lesions in inflammatory bowel disease

用于对炎症性肠病中的炎症-发育不良-癌变序列病变进行分类的转录组评分

Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST Study

炎症性肠病日常临床实践中的疾病监测及其对治疗决策的影响：来自炎症性肠病-PODCAST研究的真实世界证据

The identification of blood-derived response eQTLs reveals complex effects of regulatory variants on inflammatory and infectious disease risk.

血液衍生反应 eQTL 的鉴定揭示了调控变异对炎症和传染病风险的复杂影响

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary

利替利单抗治疗系统性红斑狼疮的LILAC研究A部分：简明语言摘要

Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary

LILAC 研究 B 部分：利替利单抗治疗皮肤红斑狼疮的简明摘要

Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial

Zasocitinib (TAK-279) 抑制酪氨酸激酶 2 治疗银屑病：一项随机临床试验

Editorial: Cutaneous lupus erythematosus landscape: pathophysiology, unmet needs, and related challenges in clinical practice. What is on the horizon?

社论：皮肤红斑狼疮的现状：病理生理学、未满足的需求以及临床实践中的相关挑战。未来发展趋势是什么？

Inhibition of RIPK1 kinase does not affect diabetes development: β-Cells survive RIPK1 activation

抑制RIPK1激酶并不影响糖尿病的发生发展：β细胞在RIPK1激活后仍能存活。